Your patients expect clearer skin
COSENTYX provides skin results you can see
Your patients expect clearer skin
COSENTYX provides skin results you can see
Adult Pivotal Studies
In the 300-mg arm (n=245) of the ERASURE study at Week 121*:
of patients achieved PASI 75, and of those, 70%
achieved PASI 90†
In the 300-mg arm (n=245) of the ERASURE study at Week 121*:
of patients achieved
PASI 75,
and of those, 70%
achieved PASI 90†
- The majority of patients achieved clear or almost clear skin1*
- Over 80% of patients on COSENTYX 300 mg in the ERASURE and FIXTURE studies who achieved PASI 75 at Week 12 sustained their response at Week 521‡
*In ERASURE, % of patients achieving an end point on 150 mg (n=245) vs placebo (n=248) at Week 12: PASI 75 (71 vs 4),
IGA 0 or 1 (51 vs 2), and PASI 90 (39 vs 1). In FIXTURE,
results on 300 mg (n=327) vs placebo (n=326) at Week 12: PASI 75 (76 vs 5), IGA 0 or 1 (62 vs 3), and PASI 90 (54 vs 2).
In FIXTURE, results on 150 mg (n=327) vs placebo at Week 12: PASI 75 (67 vs 5), IGA 0 or 1 (51 vs 3), and PASI 90 (42
vs 2). At Week 12 in ERASURE, 65% of patients on COSENTYX 300 mg achieved IGA mod 2011 0 or 1 vs 2% of patients on placebo.
All comparisons, P<0.001. Results similar in FEATURE and JUNCTURE.1,2
†In ERASURE, 59% of patients achieved PASI 90 on 300 mg vs 1% for placebo at Week 12.1
‡In the COSENTYX 300-mg treatment arm, 81% and 84% of patients in ERASURE and FIXTURE, respectively, who achieved PASI 75 at Week 12 sustained their response
at Week 52. In the COSENTYX 150-mg treatment arm, 72% and 82% of patients in ERASURE and FIXTURE, respectively, who achieved PASI 75 at Week 12 sustained their
response at Week 52.1
See faster-onset data
vs comparator at Week 4
See faster-onset data
vs comparator at Week 4
See PASI 100 data
vs comparator
See PASI 100 data
vs comparator
See 5-year
efficacy data
See 5-year
efficacy data
Click here to see study designs.
IGA=Investigator's Global Assessment; PASI=Psoriasis Area and Severity Index.
References: 1. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2021. 2. Langley RG et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. 3. Bagel et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571-579. 4. Data on file. CAIN457A2326 Week 16 Analysis. Novartis Pharmaceuticals Corp; January 2018. 5. Stelara [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2018. 6. Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 [Epub ahead of print]. doi: 10.1111/jdv.14878. 7. Data on file. CAIN457A2304E1 Clinical Study Report. Novartis Pharmaceuticals Corp; February 2018.